1. Oral administration of a chymotrypsin-labile peptide - a new test of exocrine pancreatic function in man (PFT);Gyr, K.; Stalder, G.A.; Schiffmann, C.; Fehr, C.; Vonderschmitt, D.; Fahrlaender, H.;Gut,1976
2. The diagnostic value of the oral pancreatic function test;Mitchell, C.J.; Humphrey, C.S.; Bullen, A.W.; Kelleher, J.;Scand J Gastroenterol,1978
3. Diagnosis of exocrine pancreatic insufficiency in cystic fibrosis by the synthetic peptide N-benzoyl-L-tyrosyl-p-aminobenzoic acid;Nousia-Arvanitakis, S.; Arvanitakis, C.; Desai, N.; Greenberger, N.J.;J Pediatr,1978
4. Oral administration of chymotrypsin labile peptide for a new test of exocrine pancreatic function (PFT) in comparison with pancreozymin-secretin test;Imamura, K.; Nakamura, T.; Miyazawa, T.; Abe, Y.; Kobayashi, M.; Takebe, K.;Am J Gastroenteirol,1978
5. Etude indirecte de la secretion exocrine du pancreas par administration orale d'un peptide synthetique (PABA test);Ribet, A.; Frexinos, J.; Escourrou, J.; Vaysse, N.; Arany, Y.; Varignon, M.;Gastroenterol Clin Biol,1979